Julie B. Feder
Chief Financial OfficerMs. Julie B. Feder serves as Chief Financial Officer of Obsidian Therapeutics, Inc. since January 2026. She served as Chief Financial Officer of Aura Biosciences, Inc. since August 2018 until September 23, 2024 and served as Advisor since September 23, 2024 until October 25, 2024 and served as Secretary and Treasurer. She served as Chief Financial Officer at Verastem, Inc. since July 10, 2017 until May 30, 2018. Ms. Feder joined Verastem from the Clinton Health Access Initiative, Inc., where she served as Chief Financial Officer for six years. At CHAI, Ms. Feder was responsible for managing a global team across multiple departments and developed the global finance strategy and internal audit, treasury and global payroll functions. She also led multiple financial and operational initiatives and was a key member of the CHAI leadership team. Prior to joining CHAI, Ms. Feder spent three years at Genzyme Corporation, first as Vice President of Internal Audit and also as Finance Integration Leader. In these roles, she managed the day to day operations of Genzyme's global internal audit function, while leading the Genzyme Global Finance integration into Sanofi's organization following Sanofi's acquisition of Genzyme. Ms. Feder began her career at Deloitte & Touche LLP, where she was Senior Manager of Audit, Consulting and Enterprise Risk Services and served leading organizations in healthcare, including Genzyme Corporation, Children's Hospital Boston, Dana Farber Cancer Center, Boston Scientific Corporation and Yale New Haven Hospital. Ms. Feder holds a Bachelor of Science in Accounting from Yeshiva University's Sy Syms School of Business.
Positions
- Company NameObsidian Therapeutics, Inc.Stock CodeOBXPositionChief Financial OfficerColleagues
